During the extension periods, the reduction in SBP was maintained in the dapagliflozin group, but patients in the glipizide group continued to show no meaningful change in mean SBP [week 104, −3.00 vs 0.89mmHg, respectively; week 208, −3.69 vs −0.02mmHg, respectively; difference, −3.67mmHg (95% CI −5.92, −1.41); Figure1C].